.
Press 2022
|
Dec 28, 2022 |
|
Biostage Selects IQVIA to Manage its FDA-Approved Clinical Trial in Severe Esophageal Disease, including Cancer
|
|
Dec 23, 2022 |
|
New Publication Demonstrates Rapid Esophageal Regeneration using the Biostage Esophageal Implant
|
|
Oct 25, 2022 |
|
Biostage Receives U.S. Patent for Cellularized Patch-Based Scaffolds for Organ Repair
|
|
Aug 08, 2022 |
|
Biostage Announces Appointment of New Chief Financial Officer
|
|
Aug 04, 2022 |
|
Biostage Reports Corporate Highlights and Second Quarter Financial Results
|
|
Aug 04, 2022 |
|
Biostage Schedules Conference Call and Webcast for Q2 2022 Results
|
|
Jun 15, 2022 |
|
Biostage Announces Publication of Mechanical Strength Data for Regenerated Esophageal Tissue in Journal of Biomechanics
|
|
May 16, 2022 |
|
Biostage Reports Q1 2022 Financial Results and Corporate Highlights
|
|
May 13, 2022 |
|
Biostage Announces $5.1 Million Financing to Advance Clinical Trial
|
|
May 10, 2022 |
|
Biostage Schedules Conference Call and Webcast for Q1 2022 Results
|
|
Apr 11, 2022 |
|
Biostage Further Strengthens IP Portfolio with Additional Patent for Regeneration and Repair of the Bronchus
|
|
Apr 01, 2022 |
|
Biostage Reports Fourth Quarter and Fiscal Year 2021 Financial Results
|
|
Mar 30, 2022 |
|
Biostage Announces Conference Call and Webcast to Discuss Fourth Quarter and Full Year 2021 Financial Results
|
|
Jan 25, 2022 |
|
Biostage Announces Court's Preliminary Injunction Order Requiring its Insurance Carrier to Continue Paying for Defense
|
|
Jan 25, 2022 |
|
Biostage Announces "Meet the Founder, New Chairman and Interim CEO" Webinar
|
|
Jan 10, 2022 |
|
New Paper Shows Biostage's Esophageal Implant Regenerates the Esophagus in Piglets
|